Revenue

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Revenue

Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

	Three Months Ended March 31, 2025						Three Months Ended March 31, 2024
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	965	$	965	$	—	$	928	$	928
Other	—		295		295		—		298		298
Total	—		1,260		1,260		—		1,226		1,226
Nutritional Products —
Pediatric Nutritionals	588		453		1,041		514		495		1,009
Adult Nutritionals	367		738		1,105		364		695		1,059
Total	955		1,191		2,146		878		1,190		2,068
Diagnostic Products —
Core Laboratory	332		845		1,177		310		895		1,205
Molecular	40		82		122		42		87		129
Point of Care	100		42		142		98		41		139
Rapid Diagnostics	399		214		613		481		260		741
Total	871		1,183		2,054		931		1,283		2,214
Medical Devices —
Rhythm Management	304		281		585		271		291		562
Electrophysiology	299		330		629		269		318		587
Heart Failure	262		77		339		237		68		305
Vascular	268		442		710		254		435		689
Structural Heart	282		295		577		233		282		515
Neuromodulation	176		52		228		181		45		226
Diabetes Care	748		1,079		1,827		589		980		1,569
Total	2,339		2,556		4,895		2,034		2,419		4,453
Other	3		—		3		3		—		3
Total	$	4,168	$	6,190	$	10,358	$	3,846	$	6,118	$	9,964

Remaining Performance Obligations

As of March 31, 2025, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was $5.7 billion in the Diagnostic Products segment and $423 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 55 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2024	$	568
Unearned revenue from cash received during the period	132
Revenue recognized related to contract liability balance	(99)
Balance at March 31, 2025	$	601